Evaluation of the long-term efficacy and safety of zolpidem-MR [modified release] 12.5 mg compared to placebo, when both are administered over a long-term period 'as needed', in patients with chronic primary insomnia

Trial Profile

Evaluation of the long-term efficacy and safety of zolpidem-MR [modified release] 12.5 mg compared to placebo, when both are administered over a long-term period 'as needed', in patients with chronic primary insomnia

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2009

At a glance

  • Drugs Zolpidem (Primary)
  • Indications Insomnia
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms ZOLONG
  • Sponsors Sanofi
  • Most Recent Events

    • 08 Apr 2009 Actual end date (Jan 2006) added as reported by ClinicalTrials.gov.
    • 29 Jun 2007 Results have been reported.
    • 15 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top